Abstract 4606
Background
ENZA, a potent androgen receptor inhibitor, provides benefit in men with castration-resistant prostate cancer (CRPC). In post hoc analyses, the role of ENZA + ADT in mHSPC patients (pts) randomized within the multinational, double-blind, PBO-controlled, Phase 3 ARCHES study (NCT02677896) was determined by disease volume and risk group stratification.
Methods
mHSPC pts were randomized 1:1 to ENZA (160 mg/day) + ADT or PBO + ADT. The primary endpoint was radiographic progression-free survival (rPFS). Secondary endpoints included prostate-specific antigen (PSA) progression and radiographic responses, overall survival (OS), and quality of life (QoL). Analyses were completed by CHAARTED-defined disease volume and LATITUDE-defined risk groups.
Results
1150 pts were randomized (ENZA + ADT, n = 574; PBO + ADT, n = 576). Median follow-up was 14.4 months. ENZA + ADT significantly improved rPFS (hazard ratio [95% CI] 0.39 [0.30, 0.50]; p < 0.0001). ENZA + ADT pts significantly benefited from prolonged rPFS in all subgroups (Table). Significant treatment benefits were observed with ENZA + ADT in several secondary clinical endpoints in the overall population and in both high and low disease volume and risk groups (Table). High QoL at baseline was maintained over time. OS data are immature. Adverse events (AEs) were reported in 85.1% of ENZA + ADT vs. 85.9% of PBO + ADT pts, with no unexpected AEs.Table:
853P
Overall (n = 1150) | Low-volume diseasea (n = 423) | High-volume diseasea (n = 727) | Low riskb (n = 556) | High riskb (n = 511) | |
---|---|---|---|---|---|
HR (95% CI)c | |||||
Primary endpoint | |||||
rPFSd | 0.39 (0.30, 0.50) | 0.25 (0.14, 0.46) | 0.43 (0.33, 0.57) | 0.42 (0.28, 0.62) | 0.34 (0.25, 0.47) |
Secondary endpoints | |||||
Time to PSA progression | 0.19 (0.13, 0.26) | 0.08 (0.03, 0.20) | 0.22 (0.16, 0.32) | 0.14 (0.08, 0.25) | 0.21 (0.14, 0.31) |
Time to castration resistance | 0.28 (0.22, 0.36) | 0.18 (0.10, 0.32) | 0.32 (0.24, 0.41) | 0.27 (0.18, 0.39) | 0.27 (0.20, 0.37) |
Time to first SSE | 0.52 (0.33, 0.80) | 0.25 (0.07, 0.91) | 0.59 (0.37, 0.95) | 0.39 (0.19, 0.81) | 0.56 (0.32, 0.98) |
Time to new antineoplastic therapy | 0.28 (0.20, 0.40) | 0.39 (0.18, 0.82) | 0.27 (0.18, 0.40) | 0.28 (0.16, 0.50) | 0.28 (0.18, 0.43) |
Rate difference (95% CI)e | |||||
PSA undetectable (<0.2 ng/mL) rate,f % | 50.5 (45.3, 55.7) | 48.4 (39.3, 57.4) | 50.7 (44.5, 57.0) | 54.7 (47.2, 62.1) | 46.0 (38.5, 53.5) |
ORR,f % | 19.3 (10.4, 28.2) | 21.1 (5.0, 37.3) | 18.6 (7.9, 29.3) | 16.4 (2.9, 29.9) | 21.7 (9.8, 33.5) |
Defined as per CHAARTED trial criteria; high volume is defined as the presence of visceral metastases or ≥ 4 bone lesions with ≥1 beyond the vertebral bodies and pelvis (Sweeney et al, New Engl J Med 2014);
bDefined as per LATITUDE trial criteria; high-risk patients had ≥2 of the following: Gleason score of ≥ 8 (scale of 2–10), ≥3 bone lesions and/or the presence of measurable visceral metastasis (Fizazi et al, New Engl J Med 2017);
cHR < 1 favors ENZA + ADT; HR > 1 favors PBO + ADT;
dAssessed by ICR or death within 24 weeks of treatment discontinuation;
eDifference >0 favors ENZA + ADT; difference <0 favors PBO + ADT;
fOf those with detectable PSA or measurable disease at baseline, respectively. ADT=androgen deprivation therapy; CI=confidence interval; ENZA=enzalutamide; HR=hazard ratio; ICR=independent central review; PBO=placebo; PSA=prostate-specific antigen; ORR=objective response rate; OS=overall survival; QoL=quality of life; rPFS=radiographic progression free survival; SSE=symptomatic skeletal event.
Conclusions
ENZA + ADT treatment showed efficacy benefit across all mHSPC pts, irrespective of disease volume and risk group. Similar delays in rPFS, symptomatic skeletal events, PSA progression, castration resistance, and improvements in radiographic responses and PSA declines, with maintenance of high QoL over time, were observed. Preliminary safety analysis appears consistent with the safety profile of ENZA in previous CRPC clinical trials.
Clinical trial identification
NCT02677896.
Editorial acknowledgement
Beatrice Vetter-Ceriotti and Lauren Smith from Complete HealthVizion, funded by the study sponsors.
Legal entity responsible for the study
Astellas Pharma Inc. and Medivation LLC, a Pfizer Company, the co-developers of enzalutamide.
Funding
Astellas Pharma Inc. and Medivation LLC, a Pfizer Company, the co-developers of enzalutamide.
Disclosure
A. Stenzl: Advisory / Consultancy: Bipsen Pharma; Advisory / Consultancy: Roche; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Alere; Advisory / Consultancy: BMS; Advisory / Consultancy: Stebatiotechnology; Research grant / Funding (self): Karl Storz AG; Research grant / Funding (self): Astellas Pharma; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Medivation; Travel / Accommodation / Expenses: Ipsen Pharma; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Aventis; Travel / Accommodation / Expenses: Curevac; Travel / Accommodation / Expenses: Ferring. R.Z. Szmulewitz: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): AbbVie; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Merck; Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (self): Janssen Oncology; Advisory / Consultancy: Sanofi; Advisory / Consultancy, Research grant / Funding (self): Astellas Pharma; Advisory / Consultancy: Pfizer; Research grant / Funding (self): Incyte; Research grant / Funding (self): Macrogenics; Travel / Accommodation / Expenses: Concept Therapeutics. D.P. Petrylak: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Bellicum; Shareholder / Stockholder / Stock options: Tyme; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Merck; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Ferring; Advisory / Consultancy, Research grant / Funding (institution): Johnson & Johnson; Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Research grant / Funding (institution): Medivation, Lilly; Advisory / Consultancy, Research grant / Funding (institution): Millineum, Dendreon, Aventis; Research grant / Funding (institution): Progenics; Advisory / Consultancy, Research grant / Funding (institution): Roche Laboratories; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Innocrin; Research grant / Funding (institution): Agensys; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): Endocyte; Advisory / Consultancy, Research grant / Funding (institution): Pfizer. J. Holzbeierlein: Research grant / Funding (self): Astellas Pharma; Research grant / Funding (self): MDX Health. A. Villers: Advisory / Consultancy: Astellas France; Research grant / Funding (institution): Astellas Pharma. A.A. Azad: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas Pharma; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Sanofi; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Tolmar; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Amgen; Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis. A. Alcaraz: Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Olympus; Travel / Accommodation / Expenses: Ipsen. B.Y. Alekseev: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Astellas Pharma; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ferring; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi. T. Iguchi: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Astellas Pharma; Speaker Bureau / Expert testimony: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer. N.D. Shore: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen Scientific Affairs; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Dendreon; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Tolmar; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ferring; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Medivation/Astellas; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Myovant Sciences; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer. B. Rosbrook: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. B. Baron: Advisory / Consultancy, Full / Part-time employment: Astellas. G.P. Haas: Full / Part-time employment: Astellas Pharma. R. Morlock: Advisory / Consultancy: Abbott Medical Optics; Advisory / Consultancy: Ironwood; Advisory / Consultancy: Genentech; Full / Part-time employment: Astellas Pharma. K. Ramaswamy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. A.J. Armstrong: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Dendreon; Honoraria (institution): Janssen Oncology; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Medivation; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen Biotech; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas Scientific & Medical Affairs Inc; Research grant / Funding (institution): Gilead Sciences; Research grant / Funding (institution): Roche/Genentech; Research grant / Funding (institution): Active Biotech; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Janssen.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract